American Society of Hematology Annual Meeting 2012
American Society of Hematology Annual Meeting
Dr. Harry Buller

By:PATRICE WENDLING

SAN FRANCISCO – Reducing factor XI levels with the experimental antisense oligonucleotide FXI-ASO lowered venous thromboembolism rates after total k... More »

Dr. Thomas Martin

By:PATRICE WENDLING

SAN FRANCISCO – Combining anti-CD38 monoclonal antibodies with standard antimyeloma therapies proved highly active without excessive toxicity in new... More »

Dr. Stephan Grupp

By:PATRICE WENDLING

SAN FRANCISCO – CAR-T cell therapy drove relapsed, refractory acute lymphoblastic leukemia into complete remission in 92% or all but three of 39 chi... More »

By:PATRICE WENDLING

SAN FRANCISCO – Adding vosaroxin to cytarabine chemotherapy increased overall survival in first relapsed or refractory acute myeloid leukemia in the... More »

Dr. Rami Komrokji

By:NEIL OSTERWEIL

SAN FRANCISCO – A first-in-class investigational agent called sotatercept appears to be safe and to improve hematologic parameters in patients with ... More »

Dr. Tom van der Hulle

By:NEIL OSTERWEIL

SAN FRANCISCO – Unless there is a clear contraindication to anticoagulation therapy, cancer patients who have an incidental pulmonary embolism disco... More »

Dr. Oliver Ottmann

By:NEIL OSTERWEIL

SAN FRANCISCO– The study was small but encouraging: Among 47 older patients with newly diagnosed acute lymphoblastic leukemia positive for the Phila... More »

Dr. Joseph Alvarnas

By:PATRICE WENDLING

SAN FRANCISCO – Autologous hematopoietic stem cell transplantation should be offered to patients with HIV-related lymphomas and treatment-responsive... More »

Dr. Christoph Röllig

By:NEIL OSTERWEIL

SAN FRANCISCO – Adding a kinase inhibitor to a standard regimen for acute myeloid leukemia can prolong event-free and relapse-free survival in young... More »

Dr. Wendy Stock

By:NEIL OSTERWEIL

SAN FRANCISCO– Teens and young adults don’t like being treated like children, but they should make an exception when it comes to acute lymphoblast... More »

By:PATRICE WENDLING

SAN FRANCISCO – Ofatumumab maintenance therapy nearly doubled progression-free survival in patients with relapsed CLL, according to a preplanned int... More »

Dr. Craig Moskowitz

By:PATRICE WENDLING

SAN FRANCISCO – Early post-transplant brentuximab vedotin dramatically slows Hodgkin’s lymphoma progression in patients at high risk for relapse o... More »

Dr. Philipe Armand

By:NEIL OSTERWEIL

SAN FRANCISCO– PD-1 checkpoint inhibitors, which have shown remarkable efficacy against advanced malignant melanoma, appear to hold similar promise ... More »

Dr. Brad Kahl

By:NEIL OSTERWEIL

SAN FRANCISCO – New standards of care are hard to come by in the treatment of relapsed/refractory multiple myeloma, but interim results of a phase I... More »

By:PATRICE WENDLING

NEW ORLEANS – In routine practice, rivaroxaban was superior to low-molecular-weight heparin for venous thromboembolism prevention in older adults un... More »

Displaying results 1 to 15 out of 104
<< First « Previous Page 1-15 16-30 31-45 46-60 61-75 76-90 91-104 Next Page » Last >>